Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on blood glucose control in insulin naive type 2 diabetes failing on secondary oral hypoglycaemic agent (OHA).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
35 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Type 2 diabetes
Insulin naive diabetes
Current treatment with OHA, secondary failure
Body mass index (BMI) below 40 kg/m2
HbA1c over 8.5%
Willing and able to start with insulin therapy and to perform self-blood glucose monitoring
History of drug or alcohol abuse
Receipt of the investigational drug within the last month prior to this trial
Known or suspected allergy to trial products or related products
Severe uncontrolled hypertension
Any disease or condition, which the Investigator feels, would interfere with the trial